TOKYO -- Moderna has increased its valuation more than any other drugmaker in the world during the pandemic as new opportunities arising from the coronavirus boost sharp-focused newcomers to new heights.
Moderna's market capitalization rose by more than $130 billion between the end of September and Thursday to nearly $140 billion, according to a ranking compiled by QUICK-FactSet.
